Manipulating immune cells for adoptive immunotherapy of cancer

Current Opinion in Immunology

Volumn 27, Issue 1, 2014, Pages 46-52

  Darcy, Phillip K ^a,b,c   Neeson, Paul ^a,b   Yong, Carmen SM ^a,b,c   Kershaw, Michael H ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; NEOPLASMS; T-LYMPHOCYTES;

EID: 84894094894     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.01.008     Document Type: Review

References (84)

1. + enriched 'young' tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010, 16:6122-6131.
2. Dudley M.E., Yang J.C., Sherry R., Hughes M.S., Royal R., Kammula U., Robbins P.F., Huang J., Citrin D.E., Leitman S.F., et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
3. Kershaw M.H., Westwood J.A., Darcy P.K. Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013, 13:525-541.
4. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
5. Masopust D., Vezys V., Marzo A.L., Lefrançois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001, 291:2413-2417.
6. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005, 102:9571-9576.
7. + memory stem cells. Nat Med 2009, 15:808-813.
8. Hacein-Bey-Abina S., Garrigue A., Wang G.P., Soulier J., Lim A., Morillon E., Clappier E., Caccavelli L., Delabesse E., Beldjord K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118:3132-3142.
9. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005, 174:2591-2601.
10. Fearon E., Pardoll D., Itaya T., Golumbek P., Levitsky H., Simons J., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990, 60.
11. + helper T cells induces potent primary and secondary tumor rejection. Blood 2005, 106:2995-3003.
12. Sun J.C., Bevan M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300:339-342.
13. + T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000, 165:6047-6055.
14. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005, 434:88-93.
15. Chamoto K., Kosaka A., Tsuji T., Matsuzaki J., Sato T., Takeshima T., Iwakabe K., Togashi Y., Koda T., Nishimura T. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 2003, 94:924-928.
16. + T cells. Cancer Res 2007, 67:11428-11437.
17. + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010, 207:637-650.
18. + T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010, 207:651-667.
19. + T cell responses in antitumor immunity. Curr Opin Immunol 1998, 10:588-594.
20. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoeitic cells. Immunity 2000, 12:677-686.
21. Mattes J., Hulett M., Xie W., Hogan S., Rothenberg M.E., Foster P., Parish C. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells. J Exp Med 2003, 197:387-393.
22. Rothenberg M.E. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. Am J Respir Cell Mol Biol 1999, 21:291-295.
23. Shimoda K., van Deursen J., Sangster M.Y., Sarawar S.R., Carson R.T., Tripp R.A., Chu C., Quelle F.W., Nosaka T., Vignali D.A., et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996, 380:630-633.
24. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., Nakanishi K., Yoshida N., Kishimoto T., Akira S. Essential role of Stat6 in IL-4 signalling. Nature 1996, 380:627-630.
25. Zou W., Restifo N. Th17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010, 10:248-256.
26. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., Hwu P., Restifo N.P., Overwijk W.W., Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009, 31:787-798.
27. Braza M.S., Klein B., Fiol G., Rossi J.-F. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica 2011, 96:400-407.
28. Burjanadzé M., Condomines M., Reme T., Quittet P., Latry P., Lugagne C., Romagne F., Morel Y., Rossi J.F., Klein B., et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007, 139:206-216.
29. D'Asaro M., La Mendola C., Di Liberto D., Orlando V., Todaro M., Spina M., Guggino G., Meraviglia S., Caccamo N., Messina A., et al. Vγ9Vδ2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010, 184:3260-3268.
30. Kunzmann V., Bauer E., Feurle J., Tony F.W., Hans-Peter, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
31. Saitoh A., Narita M., Watanabe N., Tochiki N., Satoh N., Takizawa J., Furukawa T., Toba K., Aizawa Y., Shinada S., et al. Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol 2008, 25:137-147.
32. Corvaisier M., Moreau-Aubry A., Diez E., Bennouna J., Mosnier J.-F., Scotet E., Bonneville M., Jotereau F. Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol 2005, 175:5481-5488.
33. Kobayashi H., Tanaka Y., Yagi J., Osaka Y., Nakazawa H., Uchiyama T., Minato N., Toma H. Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007, 56:469-476.
34. Viey E., Fromont G., Escudier B., Morel Y., Da Rocha S., Chouaib S., Caignard A. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005, 174:1338-1347.
35. Viey E., Lucas C., Romagne F., Escudier B., Chouaib S., Caignard A. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vg9Vd2 T cells from renal cell carcinoma patients. J Immunother 2008, 31:313-323. 10.1097/CJI.1090b1013e3181609988.
36. Bonneville M., O'Brien R.L., Born W.K. γδ T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010, 10:467-478.
37. Gober H.-J., Kistowska M., Angman L., Jenö P., Mori L., De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003, 197:163-168.
38. Lança T., Correia D.V., Moita C.F., Raquel H., Neves-Costa A., Ferreira C., Ramalho J.S., Barata J.T., Moita L.F., Gomes A.Q., et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity. Blood 2010, 115:2407-2411.
39. Toutirais O., Cabillic F., Le Friec G., Salot S., Loyer P., Le Gallo M., Desille M., de La Pintière C.T., Daniel P., Bouet F., et al. DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vγ9Vδ2 T cells. Eur J Immunol 2009, 39:1361-1368.
40. Gertner-Dardenne J., Castellano R., Mamessier E., Garbit S., Kochbati E., Etienne A., Charbonnier A., Collette Y., Vey N., Olive D. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol 2012, 188:4701-4708.
41. Harly C., Guillaume Y., Nedellec S., Peigné C.-M., Mönkkönen H., Mönkkönen J., Li J., Kuball J., Adams E.J., Netzer S., et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood 2012, 120:2269-2279.
42. Palakodeti A., Sandstrom A., Sundaresan L., Harly C., Nedellec S., Olive D., Scotet E., Bonneville M., Adams E.J. The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies. J Biol Chem 2012, 287:32780-32790.
43. Morita C.T., Verma S., Aparicio P., Martinez-A C., Spits H., Brenner M.B. Functionally distinct subsets of human γ/δ T cells. Eur J Immunol 1991, 21:2999-3007.
44. Inatsuka C., Yang Y., Gad E., Rastetter L., Disis M., Lu H. Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunol Immunother 2013, 62:1335-1345.
45. Lança T., Costa M.F., Gonçalves-Sousa N., Rei M., Grosso A.R., Penido C., Silva-Santos B. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of Type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol 2013, 190:6673-6680.
46. Abe Y., Muto M., Nieda M., Nakagawa Y., Nicol A., Kaneko T., Goto S., Yokokawa K., Suzuki K. Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009, 37:956-968.
47. Bennouna J., Bompas E., Neidhardt E., Rolland F., Philip I., Galéa C., Salot S., Saiagh S., Audrain M., Rimbert M., et al. Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008, 57:1599-1609.
48. Kobayashi H., Tanaka Y., Yagi J., Minato N., Tanabe K. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 2011, 60:1075-1084.
49. Noguchi A., Kaneko T., Kamigaki T., Fujimoto K., Ozawa M., Saito M., Ariyoshi N., Goto S. Zoledronate-activated Vγ9γ T cell-based immunotherapy is feasible and restores the impairment of gamma; T cells in patients with solid tumors. Cytotherapy 2012, 13:92-97.
50. Sakamoto M., Nakajima J., Murakawa T., Fukami T., Yoshida Y., Murayama T., Takamoto S., Matsushita H., Kakimi K. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 2011, 34:202-211.
51. Kondo M., Sakuta K., Noguchi A., Ariyoshi N., Sato K., Sato S., Sato K., Hosoi A., Nakajima J., Yoshida Y., et al. Zoledronate facilitates large-scale ex vivo expansion of functional gamma; T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008, 10:842-856.
52. Metelitsa L.S., Weinberg K.I., Emanuel P.D., Seeger R.C. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003, 17:1068-1077.
53. Smyth M.J., Thia K.Y.T., Street S.E.A., Cretney E., Trapani J.A., Taniguchi M., Kawano T., Pelikan S.B., Crowe N.Y., Godfrey D.I. Differential tumor surveillance by natural killer (Nk) and Nkt cells. J Exp Med 2000, 191:661-668.
54. Swann J.B., Uldrich A.P., van Dommelen S., Sharkey J., Murray W.K., Godfrey D.I., Smyth M.J. Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 2009, 113:6382-6385.
55. Bellone M., Ceccon M., Grioni M., Jachetti E., Calcinotto A., Napolitano A., Freschi M., Casorati G., Dellabona P. iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS ONE 2010, 5:e8646.
56. Molling J.W., Langius J.A., Langendijk J.A., Leemans C.R., Bontkes H.J., Van Der Vliet H.J., Von Blomberg B.M., Scheper R.J., Van Den Eertwegh A.J. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007, 25:862-868.
57. Tahir S.M., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., Balk S.P., Exley M.A. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001, 167:4046-4050.
58. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S., Dhodapkar K.M., Krasovsky J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003, 197:1667-1676.
59. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., Matory Y.L., Skibber J.M., Shiloni E., Vetto J.T., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985, 313:1485-1492.
60. Phillips J.H., Lanier L.L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 1986, 164:814-825.
61. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
62. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
63. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., Eldridge P., Leung W.H., Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
64. Pegram H.J., Jackson J.T., Smyth M.J., Kershaw M.H., Darcy P.K. Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo. J Immunol 2008, 181:3449-3455.
65. Uherek C., Tonn T., Uherek B., Becker S., Schnierle B., Klingemann H.G., Wels W. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 2002, 100:1265-1273.
66. Chen Y.L., Chen S.H., Wang J.Y., Yang B.C. Fas ligand on tumor cells mediates inactivation of neutrophils. J Immunol 2003, 171:1183-1191.
67. Graf M.R., Prins R.M., Merchant R.E. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol 2001, 166:121-129.
68. Roberts M.R., Cooke K.S., Tran A.-C., Smith K.A., Lin W.Y., Wang M., Dull T.J., Farson D., Zsebo K.M., Finer M.H. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing ζ or γ signaling domains. J Immunol 1998, 161:375-384.
69. Paul S., Snary D., Hoebeke J., Allen D., Balloul J.M., Bizouarne N., Dott K., Geist M., Hilgers J., Kieny M.P., et al. Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. Hum Gene Ther 2000, 11:1417-1428.
70. Munitz A., Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy 2004, 59:268-275.
71. Simson L., Ellyard J.I., Dent L.A., Matthaei K.I., Rothenberg M.E., Foster P.S., Smyth M.J., Parish C.R. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007, 178:4222-4229.
72. Takatsu K., Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol 2008, 20:288-294.
73. Westwood J.A., Smyth M.J., Teng M.W., Moeller M., Trapani J.A., Scott A.M., Smyth F.E., Cartwright G.A., Power B.E., Honemann D., et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005, 102:19051-19056.
74. Whiteside T.L. Isolation of human NK cells and generation of LAK activity. Curr Protoc Immunol 2001, (Chapter 7): Unit 7.7.
75. Exley M.A., Wilson B., Balk S.P. Isolation and functional use of human NKT cells. Curr Protoc Immunol 2010, (Chapter 14): Unit 14.11.
76. Siegers G.M., Ribot E.J., Keating A., Foster P.J. Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer Immunol Immunother 2012, 62:571-583.
77. Radinger M., Jensen B.M., Kuehn H.S., Kirshenbaum A., Gilfillan A.M. Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood. Curr Protoc Immunol 2010, (Chapter 7): Unit 7.37.
78. Akuthota P., Shamri R., Weller P.F. Isolation of human eosinophils. Curr Protoc Immunol 2012, (Chapter 7): Unit 7.31.
79. Vijayan D. Isolation and differentiation of monocytes-macrophages from human blood. Methods Mol Biol 2012, 844:183-187.
80. Dyer K.D., Moser J.M., Czapiga M., Siegel S.J., Percopo C.M., Rosenberg H.F. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol 2008, 181:4004-4009.
81. Gennari F., Lopes L., Verhoeyen E., Marasco W., Collins M.K. Single-chain antibodies that target lentiviral vectors to MHC class II on antigen-presenting cells. Hum Gene Ther 2009, 20:554-562.
82. Leyva F.J., Anzinger J.J., McCoy J.P., Kruth H.S. Evaluation of transduction efficiency in macrophage colony-stimulating factor differentiated human macrophages using HIV-1 based lentiviral vectors. BMC Biotechnol 2011, 11:13.
83. Porter D.L., Levine B.L., Kalos M., Bagg A., June C.H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733.
84. Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S.E., Alici E. Inhibition of intracellular antiviral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. Hum Gene Ther 2012, 23:1090-1100.